Thymoma and paraneoplastic myasthenia gravis

Autoimmunity

Volumn 43, Issue 5-6, 2010, Pages 413-427

  Marx, A ^a   Willcox, N ^b   Leite, M I ^b   Chuang, W Y ^c   Schalke, B ^d   Nix, W ^e   Strbel, P ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Autoimmunity; myasthenia gravis; thymoma

Indexed keywords

AUTOIMMUNE REGULATOR PROTEIN; CHOLINERGIC RECEPTOR ANTIBODY; CONNECTIN; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 2; OCTREOTIDE; RYANODINE; TRANSCRIPTION FACTOR FOXP3; VOLTAGE GATED CALCIUM CHANNEL;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; AUTOIMMUNITY; CANCER CLASSIFICATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMMUNICATION; CELL SELECTION; CHROMOSOME 6P; CLINICAL TRIAL; DENDRITIC CELL; DISEASE CLASSIFICATION; EPITHELIUM CELL; GENE MUTATION; GENETIC POLYMORPHISM; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LUNG SMALL CELL CANCER; MACROPHAGE; MICROENVIRONMENT; MYASTHENIA GRAVIS; NATURAL KILLER CELL; PARANEOPLASTIC SYNDROME; PATHOGENESIS; PATHOGENICITY; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SEROLOGY; T LYMPHOCYTE; THYMOCYTE; THYMOMA; THYMUS;

AUTOANTIBODIES; AUTOANTIGENS; EPITHELIAL CELLS; GENES, MHC CLASS II; HUMANS; IMMUNOGLOBULIN G; LYMPHOPOIESIS; MYASTHENIA GRAVIS; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; POLYENDOCRINOPATHIES, AUTOIMMUNE; T-LYMPHOCYTES; THYMOMA; THYMUS GLAND; TRANSCRIPTION FACTORS;

EID: 77955877122     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916930903555935     Document Type: Review

References (117)

1. Graus F, Dalmau J. Paraneoplastic neurological syndromes: Diagnosis and treatment. Curr Opin Neurol 2007;20(6): 732-737.
2. Roberts A, Perera S, Lang B, Vincent A, Newsom-Davis J. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature 1985; 317(6039):737-739.
3. Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990;40(10):1552-1556.
4. Dunbar PR, Smith CL, Chao D, Salio M, Shepherd D, Mirza F, Lipp M, Lanzavecchia A, Sallusto F, Evans A, Russell-Jones R, Harris AL, Cerundolo V. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol 2000;165(11):6644-6652.
5. Maddison P, Lang B. Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer. J Neuroimmunol 2008;201-202:159-162.
6. Vrolix K, Fraussen J, Molenaar PC, Losen M, Somers V, Stinissen P, De Baets MH, Mart́nez-Mart́nez P. The autoantigen repertoire in myasthenia gravis. Autoimmunity 2010; 43(5):380-400.
7. Strobel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, Gold R, Semik M, Kiefer R, Nix W, Schalke B, Muller-Hermelink HK, Marx A. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: A retrospective analysis. J Clin Oncol 2004;22(8):1501-1509.
8. Strobel P, Murumagi A, Klein R, Luster M, Lahti M, Krohn K, Schalke B, Nix W, Gold R, Rieckmann P, Toyka K, Burek C, Rosenwald A, Muller-Hermelink HK, Pujoll-Borrell R, Meager A, Willcox N, Peterson P, Marx A. Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). J Pathol 2007;211(5): 563-571.
9. Willcox N, Schluep M, Ritter MA, Schuurman HJ, Newsom- Davis J, Christensson B. Myasthenic and nonmyasthenic thymoma. An expansion of a minor cortical epithelial cell subset? Am J Pathol 1987;127(3):447-460.
10. Hoffacker V, Schultz A, Tiesinga JJ, Gold R, Schalke B, Nix W, Kiefer R, Muller-Hermelink HK, Marx A. Thymomas alter the T-cell subset composition in the blood: A potential mechanism for thymoma-associated autoimmune disease [In Process Citation]. Blood 2000;96(12): 3872-3879.
11. Buckley C, DouekD, Newsom-Davis J, Vincent A, WillcoxN. Mature, long-lived CD4+ and CD8+T cells are generated by the thymoma in myasthenia gravis. Ann Neurol 2001; 50(1):64-72.
12. Liston A, Gray DH, Lesage S, Fletcher AL, Wilson J, Webster KE, Scott HS, Boyd RL, Peltonen L, Goodnow CC. Gene dosage-limiting role of AIRE in thymic expression, clonal deletion, and organ-specific autoimmunity. J Exp Med 2004;200(8):1015-1026.
13. Giraud M, Taubert R, Vandiedonck C, Ke X, Levi-Strauss M, Pagani F, Baralle FE, Eymard B, Tranchant C, Gajdos P, Vincent A, WillcoxN, BeesonD, Kyewski B, Garchon HJ. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 2007;448(7156): 934-937.
14. Cavadini P, Vermi W, Facchetti F, Fontana S, Nagafuchi S, Mazzolari E, Sediva A, Marrella V, Villa A, Fischer A, Notarangelo LD, Badolato R. AIRE deficiency in thymus of 2 patients with Omenn syndrome. J Clin Invest 2005;115(3): 728-732.
15. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C, Mathis D. Projection of an immunological self shadow within the thymus by the AIRE protein. Science 2002;298(5597): 1395-1401.
16. Inoue M, Starostik P, Zettl A, Ströbel P, Schwarz S, Scaravilli F, Henry K, Willcox N, Muller-Hermelink HK, Marx A. Correlating genetic aberrations with WHO-defined histology and stage across the spectrum of thymomas. Cancer Res 2003;63:3708-3715.
17. Strobel P, Chuang WY, Chuvpilo S, Zettl A, Katzenberger T, Kalbacher H, Rieckmann P, Nix W, Schalke B, Gold R, Muller-Hermelink HK, Peterson P, Marx A. Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: Role of MHCclass II and AIRE genes and genetic polymorphisms. Ann NY Acad Sci 2008;1132: 143-156.
18. Schluep M, Willcox N, Vincent A, Dhoot GK, Newsom- Davis J. Acetylcholine receptors in human thymic myoid cells in situ: An immunohistological study. Ann Neurol 1987; 22(2):212-222.
19. Newsom-Davis J, Willcox N, Schluep M, Harcourt G, Vincent A, Mossman S, Wray D, Burges J. Immunological heterogeneity and cellular mechanisms in myasthenia gravis. Ann NY Acad Sci 1987;505:12-26.
20. Hasserjian RP, Ströbel P, Marx A. Pathology of thymic tumors. Semin Thorac Cardiovasc Surg 2005;17(1): 2-11.
21. Marx A, Ströbel P, Zettl A, Chan JKC, Fukayama M, Matsuno Y, Harris NL, Kuo T, Engel PJ, Müller-Hermelink HK. Thymic epithelial tumours. Introduction on thymoma and thymic carcinoma. In: Travis WD, Brambilla E, Müller- Hermelink HK, Harris CC, editors. WHO classification of tumours of the lung, thymus, and heart. Pathology and genetics. Lyon: IARC Press; 2004.
22. Müller-Hermelink HK, Engel P, Kuo TT, Ströbel P, Marx A, Harris NL,Mö ller P, Menestrina F, ShimosatoY, Asamura H, Masaoka A, Sobin LH. Tumours of the thymus: Introduction. In: Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, editors. Tumours of the lung, pleura, thymus and heart. Pathology and genetics. Lyon: IARC; 2004. p 149-151.
23. Rossi SW, Jenkinson WE, Anderson G, Jenkinson EJ. Clonal analysis reveals a common progenitor for thymic cortical and medullary epithelium. Nature 2006;441(7096):988-991.
24. Bleul CC, Corbeaux T, Reuter A, Fisch P, Monting JS, Boehm T. Formation of a functional thymus initiated by a postnatal epithelial progenitor cell. Nature 2006;441(7096): 992-996.
25. Rodewald HR, Paul S, Haller C, Bluethmann H, Blum C. Thymus medulla consisting of epithelial islets each derived from a single progenitor. Nature 2001;414(6865):763-768.
26. Shakib S, Desanti GE, Jenkinson WE, Parnell SM, Jenkinson EJ, Anderson G. Checkpoints in the development of thymic cortical epithelial cells. J Immunol 2009;182(1): 130-137.
27. NenningerR, SchultzA,HoffackerV,HelmreichM,WilischA, Vandekerckhove B, Hunig T, Schalke B, Schneider C, Tzartos S, Kalbacher H, Muller-Hermelink HK, Marx A. Abnormal thymocyte development and generation of autoreactive T cells in mixed and cortical thymomas. Lab Invest 1998;78(6):743-753.
28. Masaoka A, Monden Y, Nakahara K, Tanioka T. Followup study of thymomas with special reference to their clinical stages. Cancer 1981;48(11):2485-2492.
29. Koga K, Matsuno Y, Noguchi M, Mukai K, Asamura H, Goya T, Shimosato Y. A review of 79 thymomas: Modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int 1994;44(5):359-367.
30. Rosai J. Histological typing of tumours of the thymus. Berlin/ Heidelberg: Springer-Verlag; 1999. p 65.
31. Vandiedonck C, Raffoux C, Eymard B, Tranchant C, Dulmet E, Krumeich S, Gajdos P, Garchon HJ. Association of HLA-A in autoimmune myasthenia gravis with thymoma. J Neuroimmunol 2009;210(1-2):120-123.
32. Maclennan CA, Vincent A, Marx A, Willcox N, Gilhus NE, Newsom-Davis J, Beeson D. Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis. J Neuroimmunol 2008;201-202:28-32.
33. Romi F, Bo L, Skeie GO, Myking A, Aarli JA, Gilhus NE. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules. J Neuroimmunol 2002;128(1-2):82-89.
34. Rieker RJ, Muley T, Klein C, Schnabel PA, Herpel E, Meister M, Schirmacher P, Dienemann H, Pfannschmidt J. An institutional study on thymomas and thymic carcinomas: Experience in 77 patients. Thorac Cardiovasc Surg 2008; 56(3):143-147.
35. Okumura M, Ohta M, Tateyama H, Nakagawa K, Matsumura A, Maeda H, Tada H, Eimoto T, Matsuda H, Masaoka A. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: A clinical study of 273 patients. Cancer 2002; 94(3):624-632.
36. Chen G, Marx A, Wen-Hu C, Yong J, Puppe B, Stroebel P, Mueller-Hermelink HK. New WHO histologic classification predicts prognosis of thymic epithelial tumors: A clinicopathologic study of 200 thymoma cases from China. Cancer 2002;95(2):420-429.
37. Quintanilla-Martinez L, Wilkins EW, Jr, Choi N, Efird J, Hug E, Harris NL. Thymoma. Histologic subclassification is an independent prognostic factor. Cancer 1994;74(2): 606-617.
38. Ho FC, Fu KH, Lam SY, Chiu SW, Chan AC, Muller-Hermelink HK. Evaluation of a histogenetic classification for thymic epithelial tumours. Histopathology 1994; 25(1):21-29.
39. D'Angelillo RM, Trodella L, Ramella S, Cellini N, Balducci M, Mantini G, Cellini F, Ciresa M, Fiore M, Evoli A, Sterzi S, Russo P, Grozio A, Cesario A, Granone P. Novel prognostic groups in thymic epithelial tumors: Assessment of risk and therapeutic strategy selection. Int J Radiat Oncol Biol Phys 2008;71(2):420-427.
40. Loehrer PJ, Sr, Wang W, Johnson DH, Ettinger DS. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An Eastern Cooperative Oncology Group Phase II trial. J Clin Oncol 2004;22(2):293-299.
41. Chalabreysse L, Roy P, Cordier JF, Loire R, Gamondes JP, Thivolet-Bejui F. Correlation of the WHO schema for the classification of thymic epithelial neoplasms with prognosis: A retrospective study of 90 tumors. Am J Surg Pathol 2002; 26(12):1605-1611.
42. Zettl A, Ströbel P, Wagner K, Katzenberger T, Ott G, Rosenwald A, Peters K, Krein A, Semik M, Müller- Hermelink HK, Marx A. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 2000;157: 257-266.
43. Fukui Y, Ishimoto T, Utsuyama M, Gyotoku T, Koga T, Nakao K, Hirokawa K, Katsuki M, Sasazuki T. Positive and negative CD4+ thymocyte selection by a single MHC class II/peptide ligand affected by its expression level in the thymus. Immunity 1997;6(4):401-410.
44. Morris CS, Esiri MM, Marx A, Newsom-Davis J. Immunocytochemical characteristics of small cell lung carcinoma associated with the Lambert-Eaton myasthenic syndrome. Am J Pathol 1992;140(4):839-845.
45. Chuang WY, Strobel P, Gold R, Nix W, Schalke B, Kiefer R, Opitz A, Klinker E, Muller-Hermelink HK, Marx A. A CTLA4 high genotype is associated with myasthenia gravis in thymoma patients. Ann Neurol 2005;58(4): 644-648.
46. Strauss AJ, Kemp PG, Jr. Serum autoantibodies in myasthenia gravis and thymoma: Selective affinity for I-bands of striated muscle as a guide to identification of antigen(s). J Immunol 1967;99(5):945-953.
47. Gilhus NE, Aarli JA, Christensson B, Matre R. Rabbit antiserum to a citric acid extract of human skeletal muscle staining thymomas from myasthenia gravis patients. J Neuroimmunol 1984;7(1):55-64.
48. Aarli JA, Stefansson K, Marton LS, Wollmann RL. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin Exp Immunol 1990;82(2): 284-288.
49. Gautel M, Lakey A, Barlow DP, Holmes Z, Scales S, Leonard K, Labeit S, Mygland A, Gilhus NE, Aarli JA. Titin antibodies in myasthenia gravis: Identification of a major immunogenic region of titin. Neurology 1993;43(8): 1581-1585.
50. Skeie GO, Freiburg A, Kolmerer B, Labeit S, Aarli JA, Appiah-Boadu S, Gilhus NE. Titin transcripts in thymomas. J Autoimmun 1997;10(6):551-557.
51. Mygland A, Kuwajima G, Mikoshiba K, Tysnes OB, Aarli JA, Gilhus NE. Thymomas express epitopes shared by the ryanodine receptor. J Neuroimmunol 1995;62(1): 79-83.
52. Kirchner T, Hoppe F, Muller-Hermelink HK, Schalke B, Tzartos S. Acetylcholine receptor epitopes on epithelial cells of thymoma in myasthenia gravis [letter]. Lancet 1987; 1(8526):218.
53. Shiono H, Roxanis I, Zhang W, Sims GP, Meager A, Jacobson LW, Liu JL, Matthews I, Wong YL, Bonifati M, Micklem K, Stott DI, Todd JA, Beeson D, Vincent A, Willcox N. Scenarios for autoimmunization of Tand B cells in myasthenia gravis. Ann NY Acad Sci 2003;998: 237-256.
54. Andreetta F, Baggi F, Antozzi C, Torchiana E, Bernasconi P, Simoncini O, Cornelio F, Mantegazza R. Acetylcholine receptor alpha-subunit isoforms are differentially expressed in thymuses from myasthenic patients. Am J Pathol 1997; 150(1):341-348.
55. Siara J, Rudel R, Marx A. Absence of acetylcholine-induced current in epithelial cells from thymus glands and thymomas of myasthenia gravis patients. Neurology 1991;41(1): 128-131.
56. Romi F, Skeie GO, Gilhus NE, Aarli JA. Striational antibodies in myasthenia gravis: Reactivity and possible clinical significance. Arch Neurol 2005;62(3):442-446.
57. Skeie GO, Romi F. Paraneoplastic myasthenia gravis: Immunological and clinical aspects. Eur J Neurol 2008; 15(10):1029-1033.
58. Dhamija R, Tan KM, Pittock SJ, Foxx-Orenstein A, Benarroch E, Lennon VA. Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility. Clin Gastroenterol Hepatol 2008;6(9):988-992.
59. Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008;70(20):1883-1890.
60. Bofill M, Janossy G, WillcoxN, Chilosi M, Trejdosiewicz LK, Newsom-Davis J. Microenvironments in the normal thymus and the thymus in myasthenia gravis. Am J Pathol 1985; 119(3):462-473.
61. Janossy G, Bofill M, Trejdosiewicz LK, Willcox HN, Chilosi M. Cellular differentiation of lymphoid subpopulations and their microenvironments in the human thymus. Curr Top Pathol 1986;75:89-125.
62. Roxanis I, Micklem K, Willcox N. True epithelial hyperplasia in the thymus of early-onset myasthenia gravis patients: Implications for immunopathogenesis. J Neuroimmunol 2001;112(1-2):163-173.
63. Safar D, Aime C, Cohen-Kaminsky S, Berrih-Aknin S. Antibodies to thymic epithelial cells in myasthenia gravis. J Neuroimmunol 1991;35(1-3):101-110.
64. Leite MI, Jones M, Strobel P, Marx A, Gold R, Niks E, Verschuuren JJ, Berrih-Aknin S, Scaravilli F, Canelhas A, Morgan BP, Vincent A, Willcox N. Myasthenia gravis thymus: Complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status. Am J Pathol 2007;171(3): 893-905.
65. Thomas JA, Willcox HN, Newsom-Davis J. Immunohistological studies of the thymus in myasthenia gravis. Correlation with clinical state and thymocyte culture responses. J Neuroimmunol 1982;3(4):319-335.
66. Hill ME, Shiono H, Newsom-Davis J, Willcox N. The myasthenia gravis thymus: A rare source of human autoantibody-secreting plasma cells for testing potential therapeutics. J Neuroimmunol 2008;201-202:50-56.
67. Roxanis I, Micklem K, McConville J, Newsom-Davis J, WillcoxN. Thymicmyoid cells and germinal center formation in myasthenia gravis; possible roles in pathogenesis. J Neuroimmunol 2002;125(1-2):185-197.
68. Leite MI, Jacob S, Viegas S, Cossins J, Clover L, Morgan BP, Beeson D, Willcox N, Vincent A. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008;131(Pt 7):1940-1952. (Pubitemid 351957451)
69. Strobel P, Rosenwald A, Beyersdorf N, Kerkau T, Elert O, Murumagi A, Sillanpaa N, Peterson P, Hummel V, Rieckmann P, Burek C, Schalke B, Nix W, Kiefer R, Muller-Hermelink HK, Marx A. Selective loss of regulatory T cells in thymomas. Ann Neurol 2004;56(6): 901-904.
70. Sommer N, Harcourt GC, Willcox N, Beeson D, Newsom- Davis J. Acetylcholine receptor-reactive T lymphocytes from healthy subjects and myasthenia gravis patients. Neurology 1991;41(8):1270-1276.
71. Melms A, Chrestel S, Schalke BC, Wekerle H, Mauron A, Ballivet M, Barkas T. Autoimmune T lymphocytes in myasthenia gravis. Determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene. J Clin Invest 1989;83(3): 785-790.
72. Nagvekar N, Moody AM, Moss P, Roxanis I, Curnow J, Beeson D, Pantic N, Newsom-Davis J, Vincent A, Willcox N. A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4-producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. J Clin Invest 1998;101(10): 2268-2277.
73. Sommer N, Willcox N, Harcourt GC, Newsom-Davis J. Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann Neurol 1990; 28(3):312-319.
74. Melms A, Schalke BC, Kirchner T, Muller-Hermelink HK, Albert E, Wekerle H. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J Clin Invest 1988;81(3):902-908.
75. Meager A, Peterson P, Willcox N. Hypothetical review: Thymic aberrations and type-I interferons: Attempts to deduce autoimmunizing mechanisms from unexpected clues in monogenic and paraneoplastic syndromes. Clin Exp Immunol 2008;154(1):141-151.
76. Marx A, Wilisch A, Schultz A, Greiner A, Magi B, Pallini V, Schalke B, Toyka K, Nix W, Kirchner T, Muller-Hermelink HK. Expression of neurofilaments and of a titin epitope in thymic epithelial tumors. Implications for the pathogenesis of myasthenia gravis. Am J Pathol 1996;148(6):1839-1850.
77. Meager A, Wadhwa M, Dilger P, Bird C, Thorpe R, Newsom-Davis J, Willcox N. Anti-cytokine autoantibodies in autoimmunity: Preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin- 12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol 2003;132(1):128-136.
78. Shiono H, Wong YL, Matthews I, Liu JL, ZhangW, Sims G, Meager A, Beeson D, Vincent A, Willcox N. Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int Immunol 2003;15(8): 903-913.
79. Willcox N, Leite MI, Kadota Y, Jones M, Meager A, Subrahmanyam P, Dasgupta B, Morgan BP, Vincent A. Autoimmunizing mechanisms in thymoma and thymus. Ann NY Acad Sci 2008;1132:163-173.
80. Spits H, Blom B, Jaleco AC, Weijer K, Verschuren MC, van Dongen JJ, Heemskerk MH, Res PC. Early stages in the development of human T, natural killer and thymic dendritic cells. Immunol Rev 1998;165:75-86.
81. Chi AW, Bell JJ, Zlotoff DA, Bhandoola A. Untangling the T branch of the hematopoiesis tree. Curr Opin Immunol 2009; 21(2):121-126.
82. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg MB, Sullivan JL, Jamieson BD, Zack JA, Picker LJ, Koup RA. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396(6712):690-695.
83. Sato T, Tamaoki N. Myoid cells in the human thymus and thymoma revealed by three different immunohistochemical markers for striated muscle. Acta Pathol Jpn 1989;39(8): 509-519.
84. Kirchner T, Schalke B, Melms A, von Kugelgen T, Muller-Hermelink HK. Immunohistological patterns of non-neoplastic changes in the thymus in myasthenia gravis. Virchows Arch B Cell Pathol Incl Mol Pathol 1986;52(3): 237-257.
85. Van De Velde RL, Friedman NB. Thymic myoid cells and myasthenia gravis. Am J Pathol 1970;59(2):347-368.
86. Giraud M, Beaurain G, Yamamoto AM, Eymard B, Tranchant C, Gajdos P, Garchon HJ. Linkage of HLA to myasthenia gravis and genetic heterogeneity depending on anti-titin antibodies. Neurology 2001;57(9): 1555-1560.
87. Skeie GO, Romi F, Aarli JA, Bentsen PT, Gilhus NE. Pathogenesis of myositis and myasthenia associated with titin and ryanodine receptor antibodies. Ann N Y Acad Sci 2003; 998:343-350.
88. Meloni A, Furcas M, Cetani F, Marcocci C, Falorni A, Perniola R, Pura M, Boe Wolff AS, Husebye ES, Lilic D, Ryan KR, Gennery AR, Cant AJ, Abinun M, Spickett GP, Arkwright PD, Denning D, Costigan C, Dominguez M, McConnell V, Willcox N, Meager A. Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab 2008;93(11):4389-4397.
89. Tackenberg B, Kruth J, Bartholomaeus JE, Schlegel K, Oertel WH, Willcox N, Hemmer B, Sommer N. Clonal expansions of CD4+B helper T cells in autoimmune myasthenia gravis. Eur J Immunol 2007;37(3): 849-863.
90. Tackenberg B, Nitschke M, Willcox N, Ziegler A, Nessler S, Schumm F, Oertel WH, Hemmer B, Sommer N. CD45 isoform expression in autoimmune myasthenia gravis. Autoimmunity 2003;36(2):117-121.
91. Somnier FE. Exacerbation of myasthenia gravis after removal of thymomas [see comments]. Acta Neurol Scand 1994; 90(1):56-66.
92. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis- ectodermal dystrophy. J Clin Endocrinol Metab 2006; 91(8):2843-2850.
93. Aschenbrenner K, D'Cruz LM, Vollmann EH, Hinterberger M, Emmerich J, Swee LK, Rolink A, Klein L. Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells. Nat Immunol 2007;8(4): 351-358.
94. Kisand K, Link M, Wolff AS, Meager A, Tserel L, Org T, Murumagi A, Uibo R, Willcox N, Trebusak Podkrajsek K, Battelino T, Lobell A, Kampe O, Lima K, Meloni A, Ergun-Longmire B, Maclaren NK, Perheentupa J, Krohn KJ, Scott HS, Husebye ES, Peterson P. Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. Blood 2008;112(7): 2657-2666.
95. Zhang W, Liu JL, Meager A, Newsom-Davis J, Willcox N. Autoantibodies to IL-12 in myasthenia gravis patients with thymoma: Effects on the IFN-gamma responses of healthy CD4+T cells. J Neuroimmunol 2003;139(1-2): 102-108.
96. Robinson JH, Owen JJ. Transplantation tolerance induced in foetal mouse thymus in vitro. Nature 1978;271(5647): 758-760.
97. Luther C, Poeschel S, Varga M, Melms A, Tolosa E. Decreased frequency of intrathymic regulatory T cells in patients with myasthenia-associated thymoma. J Neuroimmunol 2005;164(1-2):124-128.
98. Ströbel P, Helmreich M, Menioudakis G, Lewin SR, Rüdiger T, Bauer A, Hoffacker V, Gold R, Nix W, Schalke B, Elert O, Semik M, Müller-Hermelink HK, Marx A. Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4+T cells in thymomas. Blood 2002;100:159-166.
99. Nenninger R, Schultz A, Muller-Hermelink HK, Marx A. Abnormal T cell maturation in myasthenia gravis associated thymomas. Verh Dtsch Ges Pathol 1996;80: 256-260.
100. Anderson MS, Venanzi ES, Chen Z, Berzins SP, Benoist C, Mathis D. The cellular mechanism of AIRE control of T cell tolerance. Immunity 2005;23(2):227-239.
101. Giraud M, Vandiedonck C, Garchon HJ. Genetic factors in autoimmune myasthenia gravis. Ann NY Acad Sci 2008; 1132:180-192.
102. Meager A, Visvalingam K, Peterson P, Moll K, Murumagi A, Krohn K, Eskelin P, Perheentupa J, Husebye E, Kadota Y, Willcox N. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 2006;3(7): e289.
103. Vandiedonck C, Beaurain G, Giraud M, Hue-Beauvais C, Eymard B, Tranchant C, Gajdos P, Dausset J, Garchon HJ. Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia. Proc Natl Acad Sci USA 2004;101(43): 15464-15469.
104. Giraud M, Beaurain G, Eymard B, Tranchant C, Gajdos P, Garchon HJ. Genetic control of autoantibody expression in autoimmune myasthenia gravis: Role of the self-antigen and of HLA-linked loci. Genes Immun 2004;5(5): 398-404.
105. Marx A, Wilisch A, Schultz A, Gattenlohner S, Nenninger R, Muller-Hermelink HK. Pathogenesis of myasthenia gravis. Virchows Arch 1997;430(5):355-364.
106. Machens A, Loliger C, Pichlmeier U, Emskotter T, Busch C, Izbicki JR. Correlation of thymic pathology with HLA in myasthenia gravis. Clin Immunol 1999;91(3): 296-301.
107. Vandiedonck C, Capdevielle C, Giraud M, Krumeich S, Jais JP, Eymard B, Tranchant C, Gajdos P, Garchon HJ. Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis. Ann Neurol 2006;59(2): 404-407.
108. Lefvert AK, Zhao Y, Ramanujam R, Yu S, Pirskanen R, Hammarstrom L. PTPN22 R620W promotes production of anti-AChR autoantibodies and IL-2 in myasthenia gravis. J Neuroimmunol 2008;197(2):110-113.
109. Greve B, Hoffmann P, Illes Z, Rozsa C, Berger K,Weissert R, Melms A. The autoimmunity-related polymorphism PTPN22 1858C/T is associated with anti-titin antibodypositive myasthenia gravis. Hum Immunol 2009;70(7): 540-542.
110. Vincent A, Leite MI, Farrugia ME, Jacob S, Viegas S, Shiraishi H, Benveniste O, Morgan BP, Hilton-Jones D, Newsom-Davis J, Beeson D, Willcox N. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann NY Acad Sci 2008;1132:84-92. (Pubitemid 351841363)
111. Okumura M, Shiono H, Minami M, Inoue M, Utsumi T, Kadota Y, Sawa Y. Clinical and pathological aspects of thymic epithelial tumors. Gen Thorac Cardiovasc Surg 2008; 56(1):10-16.
112. Girard N, Mornex F, Van Houtte P, Cordier JF, van Schil P. Thymoma: A focus on current therapeutic management. J Thorac Oncol 2009;4(1):119-126.
113. Casey EM, Kiel PJ, Loehrer PJ, Sr. Clinical management of thymoma patients. Hematol Oncol Clin North Am 2008; 22(3):457-473.
114. Wright CD. Management of thymomas. Crit Rev Oncol Hematol 2008;65(2):109-120.
115. Giaccone G, Wilmink H, Paul MA, Van Der Valk P. Systemic treatment of malignant thymoma: A decade experience at a single institution. Am J Clin Oncol 2006; 29(4):336-344.
116. Lucchi M, Melfi F, Dini P, Basolo F, Viti A, Givigliano F, Angeletti CA, Mussi A. Neoadjuvant chemotherapy for stage III and IVA thymomas: A single-institution experience with a long follow-up. J Thorac Oncol 2006;1(4):308-313.
117. KissandK, BoeWolff AS, PodkrajsekKT, TserelKV, Link M, Kisand KV, Ersvaer E, Perheentupa J, Erichsen MM, Bratanic N, Meloni A, Cetani F, Perniola R, Ergun- Longmire B, Maclaren N, Krohn KJ, Pura M, Schalke B, Ströbel P, Leite MI, Battelino T, Husebye ES, Peterson P, Willcox N,Meager A. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010;207: 299-308.